Profil
Sam Barker worked as a Director of Business Development at Biodexa Pharmaceuticals Plc from 2020 to 2021.
Prior to that, he worked as a Senior Business Development and Alliance Manager at PhoreMost Ltd.
Dr. Barker received his undergraduate and doctorate degrees from The University of Exeter.
Ehemalige bekannte Positionen von Sam Barker
| Unternehmen | Position | Ende |
|---|---|---|
| BIODEXA PHARMACEUTICALS PLC | Direktor/Vorstandsmitglied | 01.08.2021 |
PhoreMost Ltd.
 PhoreMost Ltd. Pharmaceuticals: MajorHealth Technology PhoreMost Ltd. operates as a drug discovery company. It engages in identifying new druggable targets for cancer and other unmet diseases. PhoreMost uses SiteSeeker technology, a live-cell phenotypic assay system that can identify unexpected, or cryptic druggable sites in specific disease driving targets and pathways that can?t be readily seen using conventional non-cell based analytical methods. The company was founded by Christopher John Torrance and Ashok Venkitaraman on April 1, 2014 and is headquartered in Cambridge, the United Kingdom. | Corporate Officer/Principal | - |
Ausbildung von Sam Barker
| The University of Exeter | Doctorate Degree |
Erfahrungen
Besetzte Positionen
Aktive
Inaktive
Börsennotierte Unternehmen
Private Unternehmen
Beziehungen
Beziehungen ersten Grades
Unternehmen ersten Grades
Herr
Frau
Aufsichtsräte
Führungskräfte
Unternehmensverbindungen
| Börsennotierte Unternehmen | 1 |
|---|---|
| BIODEXA PHARMACEUTICALS PLC | Health Technology |
| Private Unternehmen | 1 |
|---|---|
PhoreMost Ltd.
PhoreMost Ltd. Pharmaceuticals: MajorHealth Technology PhoreMost Ltd. operates as a drug discovery company. It engages in identifying new druggable targets for cancer and other unmet diseases. PhoreMost uses SiteSeeker technology, a live-cell phenotypic assay system that can identify unexpected, or cryptic druggable sites in specific disease driving targets and pathways that can?t be readily seen using conventional non-cell based analytical methods. The company was founded by Christopher John Torrance and Ashok Venkitaraman on April 1, 2014 and is headquartered in Cambridge, the United Kingdom. | Health Technology |
